AEON Biopharma Designates Paul Lee As Chief Regulatory Office
Benzinga Newsdesk 2 months ago
NewsManagement
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S.
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the Company's regulatory leadership.